Tatiana Sofia Rodrı́guez-Reyna

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Joaquı́n Zúñiga

Instituto Nacional de Enfermedades Respiratorias

Alfredo Cruz‐Lagunas

Instituto Nacional de Enfermedades Respiratorias

Julio Granados

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

Janet Pope

Western University

Luis Jiménez-Álvarez

Instituto Nacional de Enfermedades Respiratorias

Gustavo Ramírez-Martínez

Instituto Nacional de Enfermedades Respiratorias

Maggie Larché

McMaster University

Marie Hudson

McGill University

Leland W.K. Chung

Stanford University

Paul R. Fortin

Université Laval

Cooperative Institutions

Digital Research Alliance of Canada

214

Psoriasis Association

210

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

138

McGill University

Center for Rheumatology

Jewish General Hospital

Instituto Nacional de Enfermedades Respiratorias

Universidad Nacional Autónoma de México

Inserm

Harvard University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti–topoisomerase I antibody

Arthritis & Rheumatism (2007)

Achini Perera Noreen Fertig Mary Lucas Tatiana Sofia Rodrı́guez-Reyna Paul Q. Hu

Abstract Objective To describe the clinical and laboratory features and natural history of the disease in systemic sclerosis (SSc; scleroderma) patients with anti–topoisomerase I (anti–topo I) antibody who have different skin thickness progression rates (STPRs). Methods SSc patients (n = 212) who were anti–topo I antibody positive were divided into 5 subgroups based on STPRs. Skin thickness was measured using the modified Rodnan skin thickness score (MRSS). Anti–topo I IgG antibody levels were determined. Results Sixty patients who were anti–topo I antibody positive had diffuse cutaneous SSc (dcSSc) with rapid progression, 82 had dcSSC with intermediate progression, and 29 had dcSSc with slow progression, 14 had limited cutaneous SSc (lcSSc) that became dcSSc, and 27 had lcSSc that did not change throughout. Patients beginning with lcSSc were younger at disease onset and had longer disease duration when diagnosed as having SSc. Interstitial lung disease was common and was equally distributed across the subgroups. Renal crisis occurred most often in patients with rapid progression (22%) and was absent in lcSSc patients. Cardiac involvement was most frequent in the dcSSc subgroups. Both kidney and heart disease occurred most often within 3 years after the onset of skin thickening. The 10‐year cumulative survival rate was <40% for patients with rapid and intermediate progression. Renal and cardiac causes of death were disproportionately frequent in these 2 subgroups. Anti–topo I antibody levels correlated with the STPR and the MRSS. Conclusion Anti–topo I antibody–positive patients with SSc with a rapid STPR have reduced survival rates, primarily due to early and often fatal renal and cardiac involvement. Anti–topo I antibody levels parallel the MRSS at the first visit and the STPR. This information is important for managing physicians and researchers planning clinical trials involving patients with early dcSSc.

Scleroderma (fungus)

Systemic scleroderma

Vital capacity

10.1002/art.22747

Cite

Citations (146)

Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients

Autoimmunity (2011)

Tatiana Sofia Rodrı́guez-Reyna Andrea Hinojosa‐Azaola Cynthia Martínez-Reyes Carlos A. Núñez‐Álvarez Rocío Torrico-Lavayen

Systemic sclerosis (SSc) shows variable clinical expression among different ethnic groups. Herein, we describe the clinical features, prevalence of organ involvement, and autoantibody profile in Mexican Mestizo SSc patients and we compare them with patients from other ethnic groups.We included 139 SSc patients. They underwent clinical evaluation and were tested for antinuclear antibodies (ANA), anticentromere antibodies (ACA), anti-topoisomerase I, anti-RNA polymerase III, anti-U1 RNP, anti-U3 RNP, anti-U11/U12 RNP, anti-Th/To, anti-PM-Scl, anti-Ku, antinucleosome, anti-double-stranded DNA (dsDNA), anti-Sm, anti-SSA, and anti-SSB antibodies. Female predominance (93.5%) was noted; 56.8% of patients had limited cutaneous SSc; 91% had peripheral vascular involvement; 70% had joint involvement; 27% had musculoskeletal damage; 66% had gastrointestinal involvement; 41% had interstitial lung disease; 32% had pulmonary arterial hypertension (PAH); 11% had cardiac involvement; and in 1.4% renal involvement was observed. Our patients showed lower frequency of renal crisis and higher frequency of PAH than patients from other ethnic groups; also they showed higher frequency of ACA than Japanese and African American patients, higher frequency of anti-topoisomerase I than Caucasian and African American patients, higher frequency of anti-PM-Scl and anti-Ku and lower frequency of anti-RNA Pol III than the other ethnic groups. High frequencies of antinucleosome (41%) and anti-dsDNA (63%) were identified. SSc-specific autoantibody frequencies are different in our patients and in those from other ethnic groups; associations of autoantibodies with clinical manifestations are confirmed in our patients. Ethnicity and the interaction of gene and environmental factors may influence the clinical picture and autoantibody profile in SSc patients.

Scleroderma (fungus)

10.3109/08916934.2011.592886

Cite

Citations (47)

Intron 2 and exon 3 sequences of HLA-B alleles may be involved in the susceptibility to develop Takayasu arteritis

International Journal of Cardiology (1998)

Tatiana Sofia Rodrı́guez-Reyna Joaquı́n Zúñiga Norma Salgado Betina Hernández-Martı́nez Gilberto Vargas‐Alarcón

Arteritis

Takayasu's arteritis

10.1016/s0167-5273(98)00161-2

Cite

Citations (9)

Factors associated with physical function among people with systemic sclerosis: a SPIN cohort cross-sectional study

Lara D. Veeken (2024)

Tiffany Dal Santo Danielle B. Rice Marie‐Eve Carrier Gabrielle Virgili-Gervais Brooke Levis

Abstract Objectives To compare physical function in systemic sclerosis (SSc, scleroderma) to general population normative data and identify associated factors. Methods Scleroderma Patient-centered Intervention Network Cohort participants completed the Physical Function domain of the Patient-Reported Outcomes Measurement Information System Version 2 upon enrolment. Multivariable linear regression was used to assess associations of sociodemographic, lifestyle, and disease-related variables. Results Among 2385 participants, the mean physical function T-score (43.7, SD = 8.9) was ∼2/3 of a standard deviation (SD) below the US general population (mean = 50, SD = 10). Factors associated in the multivariable analysis included older age (−0.74 points per SD years, 95% CI −0.78 to −1.08), female sex (−1.35, −2.37 to −0.34), fewer years of education (−0.41 points per SD in years, −0.75 to −0.07), being single, divorced, or widowed (−0.76, −1.48 to −0.03), smoking (−3.14, −4.42 to −1.85), alcohol consumption (0.79 points per SD drinks per week, 0.45–1.14), BMI (−1.41 points per SD, −1.75 to −1.07), diffuse subtype (−1.43, −2.23 to −0.62), gastrointestinal involvement (−2.58, −3.53 to −1.62), digital ulcers (−1.96, −2.94 to −0.98), moderate (−1.94, −2.94 to −0.93) and severe (−1.76, −3.24 to −0.28) small joint contractures, moderate (−2.10, −3.44 to −0.76) and severe (−2.54, −4.64 to −0.44) large joint contractures, interstitial lung disease (−1.52, −2.27 to −0.77), pulmonary arterial hypertension (−3.72, −4.91 to −2.52), rheumatoid arthritis (−2.10, −3.64 to −0.56) and idiopathic inflammatory myositis (−2.10, −3.63 to −0.56). Conclusion Physical function is impaired for many individuals with SSc and is associated with multiple disease factors.

Cross-sectional study

10.1093/rheumatology/keae162

Cite

Citations (1)

Temporal trends in COVID-19 outcomes in people with rheumatic diseases in Ireland: data from the COVID-19 Global Rheumatology Alliance registry

Lara D. Veeken (2022)

Richard Conway Elena Nikiphorou Christiana A. Demetriou Candice Low Kelly Leamy

Abstract Objectives Although evidence is accumulating globally, data on outcomes in rheumatic disease and COVID-19 in Ireland are limited. We used data from the COVID-19 Global Rheumatology Alliance (C19-GRA) to describe time-varying COVID-19 outcomes for people with rheumatic disease in Ireland. Methods Data entered into the C19-GRA provider registry from Ireland between 24 March 2020 and 9 July 2021 were analysed. Differences in the likelihood of hospitalization and mortality according to demographic and clinical variables were investigated using Chi-squared test or Fisher’s exact test, as appropriate. Trends in odds of hospitalization and mortality over time were investigated using logistic regression with the time period as a categorical variable. Results Of 212 cases included, 59.4% were female and median age was 58.0 years (range 13–96). Of the 212 cases, 92 (43%) were hospitalized and 22 (10.4%) died. Increasing age, a diagnosis of gout, ever smoking, glucocorticoid use, having comorbidities and specific comorbidities of cancer, cardiovascular and pulmonary disease were more common in those hospitalized. A diagnosis of inflammatory arthritis, csDMARD and/or b/tsDMARD use were less frequent in those hospitalized. Increasing age, a diagnosis of gout, ever smoking, having comorbidities and specific comorbidities of obesity, cardiovascular and pulmonary disease were more common in those who died. Odds of hospitalization or mortality did not change over time. Conclusion No temporal trend was observed in either COVID-19-related hospitalization or mortality outcomes for people with rheumatic disease in Ireland.

Odds

10.1093/rheumatology/keac142

Cite

Citations (7)

S100A8/A9 Proteins Mediate Neutrophilic Inflammation and Lung Pathology during Tuberculosis

American Journal of Respiratory and Critical Care Medicine (2013)

Radha Gopal Leticia Monin Diana Torres‐García Samantha Slight Smriti Mehra

Rationale: A hallmark of pulmonary tuberculosis (TB) is the formation of granulomas. However, the immune factors that drive the formation of a protective granuloma during latent TB, and the factors that drive the formation of inflammatory granulomas during active TB, are not well defined.Objectives: The objective of this study was to identify the underlying immune mechanisms involved in formation of inflammatory granulomas seen during active TB.Methods: The immune mediators involved in inflammatory granuloma formation during TB were assessed using human samples and experimental models of Mycobacterium tuberculosis infection, using molecular and immunologic techniques.Measurements and Main Results: We demonstrate that in human patients with active TB and in nonhuman primate models of M. tuberculosis infection, neutrophils producing S100 proteins are dominant within the inflammatory lung granulomas seen during active TB. Using the mouse model of TB, we demonstrate that the exacerbated lung inflammation seen as a result of neutrophilic accumulation is dependent on S100A8/A9 proteins. S100A8/A9 proteins promote neutrophil accumulation by inducing production of proinflammatory chemokines and cytokines, and influencing leukocyte trafficking. Importantly, serum levels of S100A8/A9 proteins along with neutrophil-associated chemokines, such as keratinocyte chemoattractant, can be used as potential surrogate biomarkers to assess lung inflammation and disease severity in human TB.Conclusions: Our results thus show a major pathologic role for S100A8/A9 proteins in mediating neutrophil accumulation and inflammation associated with TB. Thus, targeting specific molecules, such as S100A8/A9 proteins, has the potential to decrease lung tissue damage without impacting protective immunity against TB.

Proinflammatory cytokine

S100A8

S100A9

10.1164/rccm.201304-0803oc

Cite

Citations (230)

Author Index Vol. 108, 2007

Cardiology (2007)

U Niebuhr-Jørgensen Lars Ib Andersen Sung-Ju Lee Jong Kwan Park Ji-Hyuck Rhee

10.1159/000111265

Cite

Citations (0)

CXCL17 Is a Specific Diagnostic Biomarker for Severe Pandemic Influenza A(H1N1) That Predicts Poor Clinical Outcome (vol 12, 633297, 2021)

Frontiers in Immunology (2021)

José Alberto Choreño-Parra Luis Jiménez-Álvarez Gustavo Ramírez-Martínez Montserrat Sandoval-Vega Citlaltepetl Salinas‐Lara

Pandemic

Pandemic influenza

H1N1 influenza

Source

Cite

Citations (0)

Rheumatic manifestations of inﬂammatory bowel disease

World Journal of Gastroenterology (2009)

Tatiana Sofia Rodrı́guez-Reyna Cynthia Martínez-Reyes Jesús K. Yamamoto‐Furusho

This article reviews the literature concerning rheumatic manifestations of inflammatory bowel disease (IBD), including common immune-mediated pathways, frequency, clinical course and therapy.Musculoskeletal complications are frequent and well-recognized manifestations in IBD, and affect up to 33% of patients with IBD.The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations, notably in HLA-B27 transgenic rats.The autoimmune pathogenic mechanisms shared by IBD and spondyloarthropathies include genetic susceptibility to abnormal antigen presentation, aberrant recognition of self, the presence of autoantibodies against specific antigens shared by the colon and other extra-colonic tissues, and increased intestinal permeability.The response against microorganisms may have an important role through molecular mimicry and other mechanisms.Rheumatic manifestations of IBD have been divided into peripheral arthritis, and axial involvement, including sacroiliitis, with or without spondylitis, similar to idiopathic ankylosing spondylitis.Other periarticular features can occur, including enthesopathy, tendonitis, clubbing, periostitis, and granulomatous lesions of joints and bones.Osteoporosis and osteomalacia secondary to IBD and iatrogenic complications can also occur.The management of the rheumatic manifestations of IBD consists of physical therapy in combination with local injection of corticosteroids and nonsteroidal anti-inflammatory drugs; caution is in order however, because of their possible harmful effects on intestinal integrity, permeability, and even on gut inflammation.Sulfasalazine, methotrexate, azathioprine, cyclosporine and leflunomide should be used for selected indications.In some cases, tumor necrosis factor-α blocking agents should be considered as first-line therapy.

Sulfasalazine

Spondyloarthropathy

Spondylitis

10.3748/wjg.15.5517

Cite

Citations (92)

Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity

Lara D. Veeken (2019)

Boyang Zheng Tatiana Nevskaya Carl A. Baxter Dena Rosen Ramey Janet Pope

To determine whether skin score changes are associated with changes in overall disease severity, function and quality of life in early dcSSc patients.A total of 154 and 128 dcSSc patients from the Canadian Scleroderma Research Group database with 1 and 2 year follow-up and a disease duration ⩽5 years without end-stage organ damage and/or significant comorbidity at the initial visit were included. Skin was assessed using the modified Rodnan skin score (mRSS) and disease severity by the summed Medsger disease severity score (DSS) (without skin domain), physician and patient global assessments, function [HAQ disability index (HAQ-DI)] and quality of life [36-item Short Form Health Survey (SF-36) physical component summary (PCS)]. Analyses were repeated in patients with a disease duration ⩽3 years.At 2 years, 64 (50%) patients had improved skin (mRSS decrease of ⩾5 points and/or ⩾25%). Skin improvers had improved summed DSS (P = 0.002); better physician global assessments of disease activity, severity and damage (all P ⩽ 0.003); better HAQ-DI (P = 0.001) and SF-36 PCS (P = 0.005). Changes in the mRSS were positively correlated with changes in summed DSS (P = 0.006) and other disease outcomes. In the 26 (20.3%) patients with worsened skin (mRSS increase of ⩾5 points and/or ⩾25%), the summed DSS and physician global assessments were worse (P = 0.01 and P ⩽ 0.009, respectively). In the subgroup with a disease duration ⩽3 years, similar associations were found.At 1 and 2 years, overall disease improvement parallels skin improvement in early dcSSc. This is important for prognosis and reflects the value of mRSS as an outcome measure in trials with these patients.

Scleroderma (fungus)

10.1093/rheumatology/kez299

Cite

Citations (24)